Syncron and Trillium Digital Services Announce Strategic Partnership to Accelerate Aftermarket Transformation, Driving Improved Asset Utilization and Uptime for Global OEMs
22.7.2025 15:00:00 CEST | Business Wire | Press Release
Syncron, a global leader of intelligent Service Lifecycle Management (SLM) solutions, and Trillium Digital Services, a global digital advisory and services firm, today announced a partnership to unlock new aftermarket value for manufacturers worldwide. The joint agreement establishes Trillium as an official partner in Syncron’s recently relaunched partner program.
Trillium will play a key role in Syncron’s growing global partner network, helping bring decades of advisory, delivery and system integration expertise to the world’s largest OEMs and distributors to drive aftermarket revenue growth. Syncron is rapidly expanding its partner ecosystem to deliver faster, smarter, and more scalable aftermarket solutions to complex asset manufacturers and distributors in industries such as automotive, agriculture, mining and construction, and heavy machinery and industrial equipment. Understanding client value is unlocked at the intersection of technological capabilities and domain expertise, Syncron is excited to have the Trillium team as one of its first strategic partners. “Syncron's solution empowers OEMs to extend asset lifecycles, maintain visibility into reuse and remanufacturing cycles, and optimize planning for both assets and spare parts inventory while maximizing pricing strategies,” said Deborah Dull, Managing Director at Trillium Digital Services. “By enabling better utilization of existing resources, manufacturers can significantly reduce material costs and minimize their exposure to supply chain disruptions, whether from tariffs, geopolitical tensions, or other operational risks.”
“Partners like Trillium are playing a critical role in helping us better serve aftermarket customers and deliver value to manufacturers across the globe,” said Rob Joseph, VP of Partnerships at Syncron. “Our partner network enables us to more swiftly tap into market needs, develop industry-leading solutions, and respond to the global economic forces and market pressures felt by our customers, including longer equipment lifecycles, supply chain complications, and tariff uncertainty.”
Trillium joins a growing roster of system integrators, referral partners and value-added resellers (VAR) in North America and EMEA that are accelerating Syncron’s ability to drive value to manufacturers across the globe. Syncron plans to expand its partner network in APAC by the end of 2025.
“As OEMs face mounting pressures from geopolitical disruption, supply chain volatility, and shifting business models, they need partners who can help them adopt the technologies of tomorrow while optimizing today’s operations,” said Michael Ciatto, Managing Director at Trillium Digital Services. “We’re partnering with Syncron to help manufacturers make the best use of what they already have, while modernizing service delivery, enhancing visibility, and driving measurable value across their aftermarket lifecycle.”
For more information on the Syncron Partner Network, visit www.syncron.com/partners. To learn more about Trillium Digital Services, visit www.trillium.digital.
About Trillium Digital Services
Trillium Digital Services is a global advisory and technology firm that helps clients build today's business with tomorrow's technologies. From backend infrastructure to frontline operations, Trillium designs and implements digital strategies for systems integration, process automation, and AI Ops across the enterprise. With strategic advisory, implementation, and specialized staffing, we meet teams where they are on their transformation journey. Our clients need new technologies while making the most of their existing systems to create better employee experience while improving the bottom line. What sets Trillium apart is its ecosystem of technology providers, giving clients access to solutions that move with them as they accelerate responsible growth in the new digital paradigm. Trillium is headquartered in Jacksonville, FL with offices in North America, Central and South America, Europe, and India. For more, visit www.trillium.digital.
About Syncron
Syncron helps manufacturers and distributors capitalize on the new service economy by increasing customer loyalty and optimizing aftermarket profitability. Syncron’s integrated, scalable, state-of-the-art Service Lifecycle Management (SLM) cloud platform puts data at the heart of aftermarket operations to unlock service synergies, significant revenue opportunities and help companies differentiate themselves with exceptional aftermarket customer experiences. The world’s top brands trust Syncron, making it the largest privately-owned global leader in intelligent SLM SaaS solutions. For more, visit syncron.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250722294307/en/
Contacts
Press Contact
Justine Duncan
justine.duncan@syncron.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom